Sanofi India Ltd - 500674 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0880 Name of the Signatory :- GIRISH TEKCHANDANIDesignation :- Company Secretary and Compliance Officer Sanofi India Ltd - 500674 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company has provided the enclosed certificate for the quarter ended 30th June 2021 under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed: Sanofi India Ltd - 500674 - Board Meeting Intimation for Meeting Of Board Of Directors To Be Held On 27Th July 2021
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday, 27th July 2021; inter alia to consider the unaudited financial results for the quarter and half year ended 30th June 2021 (Q2).
Sanofi seeks nod to conduct phase 3 trial of its jab in India
If the firm gets approval, it will be the first global trial for a foreign covid vaccine in the country Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are as enclosed.
Sanofi to invest 400 million euros in mRNA vaccines development
The mRNA technology has proven both effective and safe so far in the vaccine response to COVID-19, including in response to the virus' variants. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the Notice to shareholders of the Company published today, in newspapers, Business Standard and Sakal.